ASCO: Survival Up With Patient-Reported Outcomes During CA Tx

Share this content:
ASCO: Survival Up With Patient-Reported Outcomes During CA Tx
ASCO: Survival Up With Patient-Reported Outcomes During CA Tx

MONDAY, June 5, 2017 (HealthDay News) -- A patient-reported outcome (PRO) intervention for symptom monitoring is associated with improved overall survival for patients treated with chemotherapy for metastatic solid tumors, according to a research letter published online June 4 in the Journal of the American Medical Association. The research was published to coincide with the annual meeting of the American Society of Clinical Oncology, held from June 2 to 6 in Chicago.

Ethan Basch, M.D., from the University of North Carolina at Chapel Hill, and colleagues examined overall survival associated with electronic patient-reported symptom monitoring versus usual care among patients initiating routine chemotherapy for metastatic solid tumors. A total of 766 participants were randomized to the usual care group or PRO group, assessed via a web-based PRO questionnaire platform. An e-mail alert was triggered to a clinical nurse when the PRO group participants reported a severe or worsening symptom.

Overall survival was assessed after 67 percent of the participants had died, at which time the median follow-up was seven years. The researchers found that the median overall survival was 31.2 and 26.0 months in the PRO and usual care groups, respectively (difference, five months; P = 0.03). The results remained significant in a multivariable model, with a hazard ratio of 0.83 (P = 0.04).

"Electronic patient-reported symptom monitoring may be considered for implementation as a part of high-quality cancer care," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Gene Tx Approved for Certain Types of B-Cell Lymphoma

Gene Tx Approved for Certain Types of B-Cell ...

First such treatment for certain types of non-Hodgkin lymphoma

Uninsurance Down by One-Third for Cancer Diagnoses in 2014

Uninsurance Down by One-Third for Cancer Diagnoses in ...

Significant decreases in uninsurance seen across all stages and sites assessed in first year of ACA

Diabetes Ups Risk of MACE in Acute Coronary Syndromes

Diabetes Ups Risk of MACE in Acute Coronary ...

Diabetes, but not pre-diabetes, tied to increased risk of major adverse cardiac events in adjusted model

is free, fast, and customized just for you!

Already a member?

Sign In Now »